Literature DB >> 16288127

Re: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

Seung-Yong Jeong, David B Chessin, Deborah Schrag, Elyn Riedel, W Douglas Wong, Jose G Guillem.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16288127     DOI： 10.1093/jnci/dji383

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  9 in total

1.  Analysis of the seventh edition of American Joint Committee on colon cancer staging.

Authors:  Yuan-Tzu Lan; Shung-Haur Yang; Shih-Ching Chang; Wen-Yih Liang; Anna Fen-Yau Li; Huann-Sheng Wang; Jeng-Kai Jiang; Wei-Shone Chen; Tzu-Chen Lin; Jen-Kou Lin
Journal:  Int J Colorectal Dis       Date:  2011-12-08       Impact factor: 2.571

2.  Integration of genetic signature and TNM staging system for predicting the relapse of locally advanced colorectal cancer.

Authors:  Junjie Peng; Zhimin Wang; Wei Chen; Yin Ding; Haifeng Wang; Hongjie Huang; Wei Huang; Sanjun Cai
Journal:  Int J Colorectal Dis       Date:  2010-08-13       Impact factor: 2.571

3.  Prognostic factors assessed for 15,096 patients with colon cancer in stages I and II.

Authors:  Pawel Mroczkowski; Uwe Schmidt; Maik Sahm; Ingo Gastinger; Hans Lippert; Rainer Kube
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

4.  Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population.

Authors:  Sharon A Dobie; Joan L Warren; Barbara Matthews; David Schwartz; Laura-Mae Baldwin; Kevin Billingsley
Journal:  Cancer       Date:  2008-02-15       Impact factor: 6.860

5.  T4N0 colon cancers should be treated like T3N1 disease.

Authors:  Dedrick Kok Hong Chan; Tian-Zhi Lim; Ker-Kan Tan
Journal:  J Gastrointest Oncol       Date:  2019-02

6.  Poor survival in stage IIB/C (T4N0) compared to stage IIIA (T1-2 N1, T1N2a) colon cancer persists even after adjusting for adequate lymph nodes retrieved and receipt of adjuvant chemotherapy.

Authors:  Quyen D Chu; Meijiao Zhou; Kaelen L Medeiros; Prakash Peddi; Mindie Kavanaugh; Xiao-Cheng Wu
Journal:  BMC Cancer       Date:  2016-07-13       Impact factor: 4.430

7.  Screening for differentially‑expressed microRNA biomarkers in Saudi colorectal cancer patients by small RNA deep sequencing.

Authors:  Yazeed A Al-Sheikh; Hazem K Ghneim; Khalid K Alharbi; Mourad A M Aboul-Soud
Journal:  Int J Mol Med       Date:  2019-10-02       Impact factor: 4.101

8.  Re-Evaluation of the Survival Paradox Between Stage IIB/IIC and Stage IIIA Colon Cancer.

Authors:  Hongbo Li; Guangshun Fu; Wei Wei; Yong Huang; Zhenguang Wang; Tao Liang; Shuyun Tian; Honggang Chen; Wei Zhang
Journal:  Front Oncol       Date:  2020-11-18       Impact factor: 6.244

9.  Predictors of recurrence free survival for patients with stage II and III colon cancer.

Authors:  Vassiliki L Tsikitis; David W Larson; Marianne Huebner; Christine M Lohse; Patricia A Thompson
Journal:  BMC Cancer       Date:  2014-05-16       Impact factor: 4.430
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.